Login    Join free Add to favorites    中文
home > news > AMSBIO: IDO Pathway Products for Immunotherapy Drug Research
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AMSBIO: IDO Pathway Products for Immunotherapy Drug Research

hits:716     Date:05/16/17
AMSBIO offer a wide range of products for IDO pathway research, including cell lines, assay kits and active proteins to be used in IDO pathway research (IDO1, IDO2 and TDO genes).

Immune evasion is one of the identifying hallmarks of cancer, and researchers worldwide are trying to identify the complex mechanisms that enable cancer cells to evade the host鈥檚 immune system. Cancer cells use the indoleamine 2,3-dioxygenase (IDO) pathway to suppress the host鈥檚 immune response in order to facilitate survival, growth, invasion, and metastasis of malignant cells. The IDO pathway is active in many tumors, providing a direct defense against T cell attack. The IDO pathway also is active in many antigen-presenting cells, resulting in peripheral tolerance to tumor-associated antigens.

Even though the first generation of immunotherapy treatments has led to some great results in previously untreatable cancer, such as melanoma, only about third of patients respond to the treatment. A second generation of immunotherapy treatment for cancer, based on IDO inhibitors, is showing promise** in pushing these positive response rates much higher.

AMSBIO offers a high-performance range of Inhibitor Screening Assay Kits designed to measure IDO1, IDO2 and TDO enzyme inhibition. These simple-to-use kits come in convenient 96- and 384-well microplate formats with enough reaction solution and enzyme to perform a total of 100 reactions.

In addition, the company has assembled a selection of stable recombinant HEK293 cell lines for monitoring IDO1 and TDO pathway activity and screening for activators or inhibitors of IDO1 and TDO in a cellular context. For studying enzyme kinetics, substrate specificity and screening inhibitors, AMSBIO also offers a comprehensive range of Human and Mouse IDO1, IDO2 and TPO His-tagged proteins.

For further information on the IDO pathway research product range please visit http://www.amsbio.com/ido-pathway.aspx or contact AMSBIO now on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

---------------------

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙